Response
Dr Ivanuša's comments are a vivid reminder that fibrinolysis will remain the standard of care for patients with ST-elevation myocardial infarction (STEMI) worldwide. In our view, it represents an excellent therapy and one that is far preferable to no reperfusion; this includes the elderly. 1,2 Even the firstgeneration fibrinolytic, streptokinase, fared equally well to percutaneous coronary intervention (PCI) within the first 3 hours in the PRAGUE 2 experience (PRimary Angioplasty in patients transferred from General community hospitals to specialized PTCA Units with or without Emergency thrombolysis). 3 Moreover, delivering PCI for STEMI, especially in off-hours, remains problematic and associated with a worse outcome. 4 The National Registry of Myocardial Infarction study, to which Ivanuša refers, actually indicates that 41% of patients presented Ͼ6 hours from symptom onset; many of those should be treated, especially if they are present within 12 hours, with appropriate clinical and ECG findings. The 25% of that sample without diagnostic ECGs cannot be characterized as undertreated STEMI. 5 Much can be done to enhance the overall outcomes of STEMI patients receiving fibrinolysis, even when resources are limited. This includes a focus on early recognition, as well as enhanced triage of those with cardiogenic shock in whom contraindications to fibrinolysis exist. Enhancing the capacity of nonphysician providers, careful assessment of ST-segment resolution postfibrinolysis, and vigilance for symptoms of recurrent ischemia will contribute to optimizing care. We heartily agree that one size will not fit all and that therapy should be individually tailored and adaptable to local environments.
